## Accepted Manuscript

Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy

Athanasios D. Anastasilakis, Dimitrios Koulaxis, Nikoleta Kefala, Stergios A. Polyzos, Jagriti Upadhyay, Eirini Pagkalidou, Fotios Economou, Chrysostomos D. Anastasilakis, Christos S. Mantzoros

PII:	S0026-0495(17)30143-9
DOI:	doi: 10.1016/j.metabol.2017.05.002
Reference:	YMETA 53599
To appear in:	Metabolism

Received date:13 April 2017Accepted date:5 May 2017



Please cite this article as: Anastasilakis Athanasios D., Koulaxis Dimitrios, Kefala Nikoleta, Polyzos Stergios A., Upadhyay Jagriti, Pagkalidou Eirini, Economou Fotios, Anastasilakis Chrysostomos D., Mantzoros Christos S., Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy, *Metabolism* (2017), doi: 10.1016/j.metabol.2017.05.002

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## ACCEPTED MANUSCRIPT

Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy

Athanasios D. Anastasilakis<sup>1</sup>, Dimitrios Koulaxis<sup>2</sup>, Nikoleta Kefala<sup>2,3</sup>, Stergios A. Polyzos<sup>4</sup>, Jagriti Upadhyay<sup>5</sup>, Eirini Pagkalidou<sup>6</sup>, Fotios Economou<sup>7</sup>, Chrysostomos D. Anastasilakis<sup>8</sup>, Christos S. Mantzoros<sup>9</sup>

<sup>1</sup> Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece;

<sup>2</sup> Department of Cardiology, 424 General Military Hospital, Thessaloniki, Greece;

<sup>3</sup> Department of Cardiology, Skaraborg Hospital, Skovde, Sweden;

<sup>4</sup> Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece;

<sup>5</sup> Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA;

<sup>6</sup> Department of Hygiene and Epidemiology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece;

<sup>7</sup> Department of Cardiology, 424 General Military Hospital, Thessaloniki, Greece;

<sup>8</sup> Department of Pharmacology, 424 General Military Hospital, Thessaloniki, Greece;

<sup>9</sup> Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

**Corresponding author:** Dr. Athanasios D. Anastasilakis, Ring Road, 564 29 N.Efkarpia, Thessaloniki, Greece, tel. +30-2310-381.697, fax: +30-2310-381.010, e-mail: a.anastasilakis@gmail.com

Download English Version:

## https://daneshyari.com/en/article/5588376

Download Persian Version:

https://daneshyari.com/article/5588376

Daneshyari.com